SCHEMBL5483651

SCHEMBL5483651

Cc1ccnc2c1NC(=O)C2(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
HTT P42858 1/20 0.41
GPR35 Q9HC97 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPY5R Q15761 7/20 0.31
KCNH2 Q12809 1/20 0.31
PDE3A Q14432 2/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
MAPK1 P28482 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30
PDPK1 O15530 1/20 0.30
HCAR3 P49019 1/20 0.30
HCAR2 Q8TDS4 1/20 0.30
MMP1 P03956 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482762 0.85 CNR1 (0.58) CNR1HTTGPR35GPR55MEN1
SCHEMBL5488440 0.72 CNR1 (0.47) CNR1HTTGPR35GPR55MEN1
SCHEMBL9841218 0.67 NPSR1 (0.43) KCNH2LMNAADORA3HCAR3HCAR2
SCHEMBL5475160 0.66 POLB (0.44) CNR1HTTGPR35GPR55MEN1
SCHEMBL5477648 0.63 CNR1 (0.35) CNR1HTTGPR35GPR55KCNH2
SCHEMBL5485435 0.63 CNR1 (0.61) CNR1HTTGPR35GPR55MEN1
SCHEMBL3855557 0.62 CNR1 (0.37) CNR1HTTGPR35GPR55KCNH2
SCHEMBL5482102 0.60 CNR1 (0.68) CNR1HTTGPR35GPR55MEN1
SCHEMBL6827374 0.60 BACE1 (0.41) KMT2ALMNAPOLBPDPK1
SCHEMBL3192059 0.59 CNR1 (0.52) CNR1HTTGPR35GPR55MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CNR1 973/4885HTT 1880/4885GPR35 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.